Am BioPark 13
93053 Regensburg, de
+49 (941) 63091970
Lophius Biosciences Appoints Robert J. Silverman as Supervisory Board Member
Former CEO of mtm Laboratories AG Robert J. Silverman was appointed to Lophius' Supervisory Board
Mr. Silverman has over 30 years of leadership experience in private and public companies across multiple segments of the healthcare industry. Currently he serves on the board of several early stage companies, including Chairman of Kiyatec, Inc., and as an Operational Partner with Gilde Healthcare, which recently closed a $285 Million fund. Mr. Silverman has considerable executive level experience in the diagnostic and pharmaceutical industry from his previous roles at Abbott Laboratories, Pasteur Merieux Connaught, Cytyc Corporation and mtm Laboratories. At mtm laboratories, an in vitro diagnostic company developing and commercializing tests for the detection and diagnosis of cervical cancer, he was instrumental as CEO in creating a successful business enterprise that resulted in the acquisition by Roche for $270 Million. He received his Bachelor of Science degree in Pharmacy from the University of Michigan, and a Master in Management from the JL Kellogg Graduate School of Management.
“On behalf of Lophius, I am pleased to welcome Bob on board. Bob has extraordinary business and operational expertise. Management and the board will greatly benefit from his broad experience as a value creating executive and as a strategic advisor in the diagnostic industry”, said Prof. Ralf Wagner, Chairman of the Lophius Biosciences Supervisory Board.
“The disruptive and proprietary technology platforms of Lophius enable the development of novel solutions in the emerging field of T cell based diagnostics. The potential exists to address significant unmet market needs, and this is greatly facilitated by the extended funding. I look forward to being a part of this exciting opportunity and to support this effort”, commented Bob Silverman, Member of the Lophius Biosciences Supervisory Board.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an email@example.com.